Redfield blasts former CDC directors for Covid criticism; government ramps up long Covid research efforts

Trump's CDC director teed off on other former agency leaders, arguing their criticism during Covid further damaged trust in public health. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

'All the shrapnel that's in my back': Defiant Robert Redfield blasts former CDC directors for criticism during Covid-19 By Lev Facher Samuel Corum/Getty Images Trump's CDC director teed off on other former agency leaders, arguing their criticism during Covid further damaged trust in public health. Read More STAT+: When a dire text message interrupted his talk, this doctor's cancer research became painfully real By Jonathan Wosen Sandy Huffaker for STAT UC San Diego oncologist Scott Lippman has spent decades treating head and neck cancer patients and trying to understand how their tumors form. Read More Biden administration ramps up long Covid research efforts following criticism By Rachel Cohrs GREG NASH/POOL/AFP via Getty Images The Biden administration announced plans to ramp up long Covid research efforts, following scathing criticism from patients and experts. Read More Sponsor content by STAT Color Code Podcast "Color Code" Podcast: STAT's podcast raising the alarm on racial inequities in American health care In this eight-episode podcast, award-winning journalist and host Nicholas St. Fleur weaves together stories and experiences of physicians, patients, historians, and other experts to illuminate the history of racism in the health care system and how it has — and continues to — impact people of color and underserved communities. Add "Color Code" to your STAT podcasts listening list and stream each episode on your preferred platform. Listen now. STAT+: Douglas Melton, noted stem cell researcher, leaves Harvard for Vertex to create diabetes treatments By Matthew Herper Stephanie Mitchell/Harvard Staff Melton, who uses stem cells to create beta cells, said he wanted to work somewhere where that kind of work was being put into practice. Read More 'We don't have a say': Siobhan Wescott wants to elevate the voices of Native Americans in public health By Isabella Cueto Alex Hogan/STAT Siobhan Wescott is an advocate for ground-up public health work that includes Native leaders and communities in collective decision-making. Read More STAT+: Bluebird, troubled gene therapy maker, to lay off employees and reduce costs By Adam Feuerstein Ruby Wallau for STAT The restructuring comes after Bluebird warned investors there was "substantial doubt" about its ability to remain solvent beyond this year. Read More STAT+: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer's drug studies By Adam Feuerstein Screen capture via Cassava Sciences It's a sign that investigations over the credibility of Cassava Sciences' drug simufilam have made physicians and patients wary. Read More Opinion: To spend less on health care, invest more in medicines By Jean-François Formela and John Stanford Adobe New medicines can significantly reduce the need for expensive emergency room visits, surgeries, hospitalizations, and long-term care. Read More Tuesday, April 5, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser